Biofarma Group
Padua, Italy (European HQ); US presence via US Pharma Lab acquisition
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (5)
○ EMA GMP
○ MHRA GMP
Quick Facts: Biofarma Group
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Padua, Italy (European HQ); US presence via US Pharma Lab acquisition
- Modalities
- Tablets, Capsules, Softgels, Gummies, Probiotics, Vitamins & Minerals, Dietary Supplements, Functional Foods, Nutraceuticals, Medical Devices (Class I/II)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Biofarma Group
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesTablets, Capsules, Softgels, Gummies, Probiotics, Vitamins & Minerals, Dietary Supplements, Functional Foods, Nutraceuticals, Medical Devices (Class I/II)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (10 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press5 articles
Broad modality coverage (10 modalities)
Recent News 5 articles
Visit Biofarma group at CPHI Frankfurt, booth 91F42 - Nutraceutical Business Review
Biofarma: Alberto Urli appointed new CEO - EFA News - European Food Agency
Biofarma acquires US Pharma Lab and focuses solely on nutraceuticals - Nutraceutical Business Review
CVC Credit supports Biofarma Group’s acquisition of US Pharma Lab - cvc.com
Biofarma Group reinforces its international presence by acquiring IHS - Nutraceutical Business Review
Frequently Asked Questions About Biofarma Group
What is Biofarma Group's CDMO Signal Score?
Biofarma Group has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Biofarma Group for a manufacturing program?
Use the free AI matchmaker to compare Biofarma Group against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.